Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Moolec Science ( (MLEC) ) is now available.
Moolec Science SA has announced an Extraordinary General Meeting (EGM) scheduled for June 16, 2025, in Buenos Aires, Argentina. The meeting will seek shareholder approval for the Business Combination Agreement (BCA) with several partners, including Bioceres Group and Union Group, and to ratify the actions of the board of directors related to the BCA. This move is significant for Moolec Science as it could impact its strategic operations and industry positioning by potentially expanding its market reach and capabilities.
The most recent analyst rating on (MLEC) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Moolec Science stock, see the MLEC Stock Forecast page.
Spark’s Take on MLEC Stock
According to Spark, TipRanks’ AI Analyst, MLEC is a Neutral.
Moolec Science’s overall stock score is primarily influenced by its financial performance challenges, including high leverage, negative margins, and poor cash flow management. Technical indicators provide some positive signals, but valuation remains a concern with a negative P/E ratio. The absence of earnings call data and corporate events means these areas do not impact the score.
To see Spark’s full report on MLEC stock, click here.
More about Moolec Science
Moolec Science SA operates in the biotechnology industry, focusing on the development of innovative solutions through the use of plant-based technology. The company is involved in creating molecular farming products, which are aimed at enhancing the nutritional value and sustainability of food products.
Average Trading Volume: 6,955
Technical Sentiment Signal: Hold
Current Market Cap: $30.7M
For an in-depth examination of MLEC stock, go to TipRanks’ Stock Analysis page.